Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inoperable Non Small Cell Lung Cancer Clear all
Completed Phase 1 Interventional

Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

NCT00330044
View directory record Official record
Conditions
Inoperable Non Small Cell Lung Cancer
Interventions
Premetrexed (Alimta), Carboplatin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00002577
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00960999
View directory record Official record
Conditions
Lung Cancer
Interventions
Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT)
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
35
States / cities
Auburn, California • Berkeley, California • Cameron Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00004202
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, chemotherapy, efaproxiral, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Not applicable Interventional

Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size

NCT01028612
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
thermal ablation with external beam radiation
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

NCT00983307
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
Erlotinib, Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dunmore, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

NCT00662311
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
vorinostat, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Not applicable Interventional Results available

Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer

NCT02262000
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Image Guided Stereotactic Ablative Radiotherapy
Radiation
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

NCT00004160
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

NCT02275806
View directory record Official record
Conditions
Lung Neoplasms, Non-Small Cell Lung Cancer
Interventions
Irinotecan, Cisplatin
Drug
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

NCT00482014
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
pemetrexed, cisplatin, carboplatin, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

NCT00365183
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Motexafin gadolinium and pemetrexed
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Huntington Beach, California • Long Beach, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Phase 3 Interventional

A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer

NCT00437749
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CBT-1, Placebo
Drug · Other
Lead sponsor
CBA Research
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Tuscon, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available

Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

NCT00664105
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Docetaxel, radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Orlando, Florida • Baltimore, Maryland • Cleveland, Ohio + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Jun 26, 2026, 8:59 PM EDT
Not listed Phase 2 Interventional

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

NCT00643318
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
CyberKnife Stereotactic Radiosurgery
Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Fresno, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

NCT00102505
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

NCT00016315
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
19
States / cities
Oakland, California • Miami, Florida • Dubuque, Iowa + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

NCT02343952
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
15
States / cities
Duarte, California • Fort Wayne, Indiana • Goshen, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

NCT00200395
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

NCT00745732
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ZD6474 (ZACTIMA), Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jun 26, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT00153803
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC
Interventions
Erlotinib (tarceva), Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Jun 26, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

NCT00042835
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jun 26, 2026, 8:59 PM EDT